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1. Introduction
The main objective of stem cell therapy is to repair the tissue with functional cells differentiated
from stem cells, and contribute to the lost organ function together with the remaining functional
native cells. Nevertheless, there also remain important questions unanswered, regarding the en‐
graftment, viability, biology and safety of transplanted stem cells, as well as interaction with the
environment. Consequently, novel molecular imaging techniques are necessary for investigat‐
ing the behaviors and the ultimate feasibility of cell transplantation therapy of stem cell.
Along with the rapid development of sensitive, noninvasive technologies, several molecular
imaging approaches have been implicated to track the fate of stem cells in vivo [1-4]. Continuous‐
ly observing the process of tissue regeneration after stem cell transplantation would markedly
improve knowledge about the underlying cellular mechanisms and analysis of the molecular
pathways that control this process. Although, this is inconsistent with the most current studies,
in which the cells are observed in hours or days time point without definite cell population. So
far, there is no single imaging modality that is ideal to observe all the relevant aspects of stem cell
therapy with a continuous manner [5]. The new development of molecular imaging technology
push the researches of stem cell therapy much closer to the single-cell level, and make the obser‐
vation of different types of stem cells more continuous and comprehensive.
2. Promises, challenges, and needs for molecular imaging of stem cell
therapy
Molecular imaging is a rapidly emerging biomedical research discipline that provides inte‐
grated information on specific molecules of interest within the cells of living subjects and
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thus holds great promise as an effective way to track certain cellular and subcellular events
of the transplanted cells [2, 6-8]. The visual representation, characterization, and quantifica‐
tion of biological processes within intact living organisms obtained from molecular imaging
techniques is particularly helpful in evaluations of the functional outcomes of cell engraft‐
ment and may shed light on the mixed findings regarding stem cell therapy. In recent years,
a variety of imaging technologies is being investigated as tools for evaluating stem cell ther‐
apy in living subjects. Molecular imaging modalities include optical bioluminescence, opti‐
cal fluorescence, targeted ultrasound, molecular magnetic resonance imaging (MRI),
magnetic resonance spectroscopy (MRS), single-photon-emission computed tomography
(SPECT), and positron emission tomography (PET) [9]. Moreover, many hybrid systems that
combine two or more of these modalities are already commercially available [9]. The use of
noninvasive, longitudinal, and quantitative imaging of the fate of stem cells can facilitate
preclinical experimental studies in animal models and can help in human stem cell therapy
trials as well.
A wide variety of stem or progenitor cells, including adult bone marrow stem cells, endo‐
thelial progenitor cells, mesenchymal stem cells (MSCs), resident cardiac stem cells, and em‐
bryonic stem cells, have been shown to have positive effects in preclinical studies and
therefore hold promise for treating and curing debilitating and deadly diseases. Several of
these types of stem cells have been tested in early-stage clinical trials, such as MSCs [10], hu‐
man embryonic stem (hES) cells [11]. However, to realize the full therapeutic potential of
stem cell technology, it will be necessary to develop novel and improved quality assess‐
ments that can be used readily to determine the exact cellular state of the transplanted cells.
After the systemic or local administrating, stem cells may be able to proliferate,  migrate
and repopulate in pathologic sites to bring tremendous therapeutic  effect.  However,  the
transplantation success is companied with risks of the stem cell  misbehavior after deliv‐
ered, especially embryonic stem cells [6, 12]. Consequently, real-time visualization of the
fate of the transplanted cells over time in vivo is a vital step to determine the efficiency of
the  implantation.  By  tracking the  optimal  number  of  transplanted cells,  researchers  can
define therapeutic windows and monitor cells growth and possible side effects for regen‐
erative therapies [13].
The ability to label and track stem cells in humans would provide a method to answer some
of the ongoing, unsolved issues in the field. The most efficacious route of delivery, the ap‐
propriate choice of stem cell type(s), the optimal cell population for treatment in a chronic
setting and the favorable time-point of cell delivery, however, is still unknown and requires
further study. A safe, noninvasive, and repeatable imaging modality that could identify in‐
jected stem cells would be able to answer questions about cell viability and retention in fu‐
ture clinical trials of stem cell therapies, as well as provide the ability to adjust the
assessment of bioactivity on the basis of actual delivered doses of cells. With the desire to
monitor stem cells long-term continuously with high temporal resolution and good biocom‐
patibility, which have the properties of differentiation and self-renew over long periods of
time, stem-cell-derived regeneration still faces in its efforts to improve.
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Despite significant progress in molecular imaging, no single technique meets all the stem
cell tracking criteria. Combined imaging modalities, such as PET-CT, are already well ac‐
cepted and offer high sensitivity and anatomical detail [14]. Multimodality imaging ap‐
proaches are likely to play an important role in illuminating different aspects of stem cell
biology in vivo and elucidating the mechanisms of tissue repair and regeneration. In brief,
noninvasive imaging stem cell therapy could provide greater insight into not only the thera‐
peutic benefit, but also the fundamental mechanisms underlying stem cell fate, migration,
survival and engraftment in vivo.
3. Approaches and implications of stem cell imaging
A number of methods are available to track stem cells by molecular imaging. In general,
there are two methods to label the cells: [1] direct labeling method, which physically intro‐
duce marker(s) into the cells before transplant; [2] indirect labeling method, which genetical‐
ly introduce reporter gene(s) into the cells before transplant. The current noninvasive
imaging approaches for tracking stem cells in vivo include imaging with magnetic particles,
radionuclides, quantum dots (QDs) and reporter genes (Figure 1).
Figure 1. Conceptual basis for noninvasive imaging of transplanted stem cells in living animals. It shows imaging tech‐
niques including magnetic resonance imaging, radionuclide imaging, quantum dots imaging and reporter gene imag‐
ing. Abbreviations: Gd-DTPA, gadolinium-diethylenetriamine penta-acetic acid; SPIO, superparamagnetic iron oxide;
99mTc, 99mTc-hexamethylpropylene amine oxime; 111In-Oxine, 111In-oxyquinoline.
Current Perspectives on Molecular Imaging for Tracking Stem Cell Therapy
http://dx.doi.org/10.5772/53028
65
Imaging of stem cell therapy requires the selection of a molecular target, an imaging probe,
and an imaging system. Specific molecular targets along with advances in imaging modali‐
ties increase the sensitivity and specificity of stem cell imaging. The commonly used label‐
ing methods are discussed below.
3.1. Magnetic particle labeling
Possessing the advantages of high spatial resolution (ranging from 50μm in animal and up
to 300μm in whole body clinical scanners) and high temporal resolution, magnetic reso‐
nance imaging (MRI) is widely used for in vivo cell tracking in preclinical and clinical stud‐
ies. The fundamental principle underlying MRI is magnetic dipoles (such as hydrogen
atoms in water and organic compounds), which align themselves when placed into a mag‐
netic field. To be tracked in ischemic tissues, stem cells need to be enriched with a contrast
agent that produces a sufficient positive or negative signal to distinguish them from the
background. One type of contrast agents is the agent containing gadolinium-diethylenetria‐
mine penta-acetic acid (Gd-DTPA), and the other type is the agent containing super para‐
magnetic iron oxide (SPIO). At present, SPIO are the preferred agent for short-term stem cell
tracking. With the high spatial and temporal resolution, MRI allows the location of iron-la‐
beled donor cells to be monitored noninvasive over several weeks in vivo [3, 15]. However, it
is difficult to distinguish iron-labeled cells from the surrounding air, hemorrhage, necrosis,
and macrophages. To address these problems, off-resonance (OR) MRI has been developed
for imaging iron-labeled hES cells to generate positive contrasts through enhancement of
signal and suppression of background tissue [3].
3.2. Radionuclide labeling
Radionuclide imaging techniques, including positron emission tomography (PET) and sin‐
gle-photon emission computed tomography (SPECT),  allow the  imaging of  radiolabeled
makers and their interaction with biochemical processes in living subjects. Current clinical
molecular imaging approaches primarily use PET or SPECT-based techniques. Compared
with MRI, PET and SPECT provide high intrinsic sensitivity (<10-11M) and can use a variety
kind of imaging agents. With the improvements in spatial resolution (1-2mm), radionuclide
imaging has been made particularly suitable for cell tracking. Direct labeling of cells with
radiometals in clinical practice has used 111In-oxyquinoline and  99mTc-hexamethylpropylene
amine oxime. Imaging plays a role in monitoring short-term cell tracking, long-term cell
survival and function, and as a surrogate marker of implant efficacy. Labeling implanted
cells with relatively long-lived isotopes, such as 111In-Oxine for SPECT and 64Cu for PET, al‐
lows shorten, real-time cell tracking, to determine biodistribution and availability in the tar‐
get organ [16].
However, these cell-labeling techniques have some significant disadvantages. They are lim‐
ited by concerns such as the potential transfer of radiotracer to nontargeted cells and poten‐
tial adverse effects of the radiotracer on stem cell viability, function, and differentiation
capacity. Thus, the effects of labeling on the capacity to differentiate stem cells of various
origins are needed to be studied.
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3.3. Nanoparticle labeling
QDs are emerging as an important class of fluorescent agents. Luminescent colloidal QDs
are inorganic semiconductor particles with physical properties that enable them to emit flu‐
orescent light from 525 to 800 nm. The nanoparticles are consisting of an inorganic core, a
shell of metal and an outer organic coating. The total diameter of quantum dots is 2–10 nm
[17], depending on the physical properties of the material due to the quantum nature of
QDs. With the capability of being excited by one single wavelength and emission light of
different wavelengths, QDs are ideal probes for multiplex imaging. By contrast, convention‐
al organic labeling agent cannot be easily synthesized to emit different colors and have nar‐
row excitation spectra and broad emission spectra, making it difficult to use these dyes for
multiplexing. Due to their extreme brightness and resistance to photobleaching [18], QDs
are appropriate for live stem cells imaging, which requires long-term observation under the
excitation light source. The approaches of QDs entering stem cells include passive loading,
receptor-mediated endocytosis or transfection. Passive loading has been found to be the
most effective method owning to the high label efficient and limited damage to surrounding
cells. QDs are capable of single quantum dot tracking, multiplex imaging, and 3-D imaging
reconstruction.
Unquestionable, quantum dots represent a novel strategy to tracking stem cells in vivo.
However, the effects of QDs on stem cell biology remain unclear because mixed results have
been reported using different stem cells or experimental protocols [19, 20]. Moreover, light
scattering limits the applicability of this approach, especially to the brain in humans, making
it difficult to use in 3D localization or quantitative estimation of cell survival. Last, several
other obstacles, including nonspecific binding to multiple molecules and the tendency for
aggregation of QDs in the cytosol must be overcome before clinical application with their
full potential.
3.4. Reporter gene labeling
Reporter gene imaging has been commonly applied to the non-invasive imaging of stem cell
therapy by studying the survival, localization, and functional effects of exogenously admin‐
istered stem cells. Imaging of gene expression in living subjects can be directed either at
genes externally transferred into cells of organ systems (transgenes) or at endogenous genes,
and the former one is used in most applications of reporter gene imaging at present. The
principle of reporter gene imaging is relatively simple. In general, reporter genes are DNA
sequences that encode for easily assayed proteins. In the case of imaging, reporter genes en‐
code for a reporter protein that, when exposed to an imaging probe, produces an analytic
signal which can be generates some form of signal that can be captured and quantified by an
imaging modality such as MRI(21), PET(22), SPECT(16), or an optical charge-coupled device
[6]. Reporter genes can be linked to a gene of interest (i.e., creation of a promoter construct)
such that the reporter protein provides a surrogate marker of that gene’s activity.
In the fields of stem-cell-driven regeneration, some conventional reporter genes, such as
green fluorescent protein (GFP) [7], firefly luciferase [23], renilla luciferase [24], and HSV1-tk
[25] allow for localization in some small living animals. Stable transfection or transduction
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with reporter genes is useful in assessing kinetic survival status of the implanted cells be‐
cause the reporter genes can be expressed as long as the cells are alive. However, the report‐
er gene approach in cell tracking requires genetic manipulations of the cells, which may lead
to insertional mutagenesis. The advances in site-specific chromosomal integration mediated
by phiC31 integrase may cast a new light in overcoming this obstacle [2]. Although small
animals or animals transparent to light can be imaged with a cooled charged coupled device
(CCD) camera, these imaging techniques are somewhat limited because of their lack of gen‐
eralizability and detailed tomographic resolution.
4. Advances in molecular imaging for tracking stem cell therapy
Stem cell therapies offer enormous potential for the treatment of a wide range of diseases
and injuries including neurodegenerative diseases, cardiovascular disease, diabetes, arthri‐
tis, spinal cord injury, stroke, and burns. More research teams are accelerating the use of
other types of adult stem cells, in particular neural stem cells for diseases where beneficial
outcome could result from either in-lineage cell replacement or extracellular factors. At the
same time, the first three trials using cells derived from pluripotent cells have begun [12].
These early trials are showing roles for stem cells both in replacing damaged tissue as well
as in providing extracellular factors that can promote endogenous cellular salvage and re‐
plenishment [26].
Clinical trials have demonstrated that stem cell therapy can improve cardiac recovery after
the acute phase of myocardial ischemia and in patients with chronic ischemic heart disease
[10]. Nevertheless, some trials have shown that conflicting results and uncertainties remain
in the case of mechanisms of action and possible ways to improve clinical impact of stem
cells in cardiac repair [27]. The public clinical trials database http://clinicaltrials.gov shows
238 clinical trials using MSCs for a very wide range of therapeutic applications. Although
early clinical trials of stem cell therapy have showed positive effect, there remains much
controversy about which cell type holds the most promise for clinical therapeutics and by
what mechanism stem cells mediate a positive effect, and further research should be able to
answer these questions.
4.1. Imaging of embryonic stem cells driven regeneration
Embryonic stem cells (ESCs) are pluripotent stem cells capable of self-renewal and differen‐
tiation into virtually all cell types [28]. Various lineages have been derived from human and
mouse ESCs, including cardiomyocytes, neurons, hematopoietic cells, osteogenic cells, hepa‐
tocytes, insulin-producing cells, keratinocytes, and endothelial cells. Given their unlimited
self-renewal and pluripotency capacity, ESCs have been regarded as a leading candidate
source for novel regenerative medicine therapy. So far, ESCs transplantation has been wide‐
ly investigated as a potential therapy for cell death-related heart disease, ischemic diseases,
CNS disorders and diabetes. However, the bottleneck of application of ESC driven regenera‐
tion is high risk of teratoma formation in vivo [3, 6].
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The concurrent development of accurate, sensitive, and noninvasive technologies capable
of monitoring ESCs engraftment in vivo has greatly accelerated basic research prior to fu‐
ture  clinical  translation.  Numerous  imaging  modalities  have  analyzed  the  behavior  of
embryonic  stem  cells  that  have  been  transplanted  to  regenerate  tissues,  which  include
MRI,  bioluminescence  imaging  (BLI),  fluorescence,  PET,  and  multimodality  approaches.
Two main PET strategies  for  embryonic  stem cell  has been used——direct  imaging [29]
and  indirect  imaging  [30].  Although  the  value  of  PET  lies  in  its  easy  accessibility  and
high-sensitivity tracking of  biomarkers,  potential  disadvantages of  PET include repeated
injection of radioactive substances into an organism with the potential to radiation accu‐
mulation [31] and adverse effect on ESCs viability and pluripotency capacity [32]. Addi‐
tionally, the short half-lives of most current available radiotracers have limited their use
for long-term tracing [33]. MRI has been used for tracking mouse ESCs [34] in the heart,
hind limbs,  brain,  lung and kidney.  Meanwhile,  MRI is  accessible for tracking ESCs en‐
graftment,  providing  detailed  morphological  and  functional  information.  Drawbacks  of
MRI include low sensitivity and being unable to quantify cell  population.  However,  the
use of CLIO-Tat peptides [35]is promising to overcome some of these limitations.  Hold‐
ing the significant advantage of high sensitivity (100-1000 cells, for more superficial ana‐
tomical  sites),  safety,  low  cost  and  the  repeated  tracking  of  small  numbers  of  labeled
cells  in  whole  body distribution without  background signal,  BLI  is  widely  used in  this
field.  Zongjin  Li,  et  al.  have compared of  BLI  and MRI for  tracking fate  of  hESCs and
hESC derived endothelial cells (hESC-ECs) in animals, data of which prove that reporter
gene of BLI is a better marker for monitoring ESCs and ESC-ECs viability and MRI is a
better marker for high-resolution detection of cell  location. Nevertheless,  at present,  bio‐
luminescence imaging still  lacks adequate tomographic resolution because of attenuation
of photons within tissues [3]. An innovative approach to combine the strengths of optical
fluorescence,  bioluminescence,  and PET is  the creation and use of a fusion reporter [36]
construct  composed  of  RFP,  Fluc,  and  HSV-tk.  This  fusion  reporter  construct  has  been
adapted  to  research  the  spatio-temporal  kinetics  of  hESC engraftment  and proliferation
in  living  subjects,  without  significant  adverse  effects  on  mouse  ESC viability,  prolifera‐
tion, differentiation, or proteomic expression [37].
4.2. Imaging of mesenchymal stem cells driven regeneration
Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal stem cells that can
differentiate into cells of the mesodermal lineage, such as bone, fat and cartilage cells, but
they also have endodermic and neuroectodermic differentiation potential. The use of MSCs
for clinical purposes takes advantage of their poor immunogenicity in vitro. Preclinical [38]
and clinical [39, 40] studies have supported the possible use of MSCs obtained from alloge‐
neic donors in the clinic. In preclinical researches, MSCs have been applied in tissue regener‐
ation, including haematopoietic organs, heart, CNS, skin, kidney, liver, lung, joint, eye,
pancreas and renal glomeruli. The current data indicate that bone-marrow-derived MSCs
were first proposed for therapeutic purposes in regenerative medicine on the basis of their
stem-cell-like qualities [41].
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The versatility of the molecular imaging method could allow cellular tracking using single
or multimodal imaging modalities. These single methods include direct labeling of cells for
transplantation with iron oxide particles for MRI, with 18F-hexafluorobenzene or 18F-FDG for
PET, or with 111In-oxine or 111In-tropolone for SPECT. Noninvasive MRI is fast becoming a
clinical favorite, though there is scope for improvement in its accuracy and sensitivity. In
that, use of superparamagnetic iron-oxide nanoparticles (SPION) as MRI contrast enhancers
may be the best select for tracking MSC treatment delivery and monitor outcome [42, 43].
Indirect labeling relies on the expression of imaging reporter genes transduced into cells be‐
fore transplantation. A classic example of using reporter gene tracing MSCs transplantation
is the research by Zachary Love, et al. They have used a triple-fusion reporter system (fluc-
mrfp-ttk) for multimodal imaging to monitor hMSCs transplanted into NOD-SCID mice.
Signals from the cubes loaded with reporter-transduced hMSCs were visible by BLI over 3
mo, meanwhile, PET data provided confirmation of the quantitative estimation of the num‐
ber of cells at one spot (cube) [44]. The reporter gene approach resulted in a reliable method
of labeling stem cells for investigations in small-animal models by use of both BLI and
small-animal PET imaging.
4.3. Imaging of neural stem cell therapy
Neural stem cells (NSCs)-driven regeneration has been proposed as a promising potential
treatment option for CNS-related disease processes, including everything from cerebrovas‐
cular disease to traumatic brain injury to degenerative diseases of the CNS. Grafted NSCs
differentiated into neurons, into oligodendrocytes undergoing remyelination and into astro‐
cytes extending processes toward damaged vasculatures [45]. At present, Applications of
NSCs therapy of neurological diseases, including Alzheimer’s disease, Huntington disease,
stroke, spinal cord injuries in preclinical researches have raised intense interest and the hope
of radical new therapies in clinical.
In contrast  to most  tissues in adults,  the central  nervous system has a low regenerative
activity, and neural stem cells reside in regions of the adult brain that are difficult to ac‐
cess  by  most  imaging modalities  [5]  owning to  tissue  depth  and the  blood-brain  barri‐
er(BBB).  The  most  promising  techniques  for  monitor  the  fate  of  NSCs in  vivo  are  MRI,
PET and optical imaging. MRI has been used in clinical practice for the past 30 years to
diagnose  brain  lesions  and is  therefore  already a  standard clinical  adjunct  for  neuropa‐
thologies.  Other  than  SPIO,  which  is  the  most  studied  and  preferred  contrast  agent  of
MRI, magnetic resonance reporter genes [46] are another possible means of magnetic res‐
onance labeling NSCs.  However,  this  technique is  still  in  its  infancy,  further  study into
the possibility of magnetic resonance reporter genes is needed before this technology can
be used for NSCs. MRI has been used in tracing neural stem cells labeled with SPIO in
patient  with  brain  trauma  [47].  The  hypointense  signal  generated  by  the  cells  demon‐
strated cell trace from the implantation site to the periphery of the lesion the first week,
and then disappeared by the seventh week, which the group attributed to NSC prolifera‐
tion.  PET  has  been  used  clinically  for  the  past  20  years  to  assess  for  neurotransmitter
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changes in  a  wide variety of  disease processes,  including Parkinson’s  disease,  Alzheim‐
er’s  disease,  Huntington’s  disease  and  psychiatric  illnesses.  In  vivo  PET  imaging  for
NSCs  requires  the  potential  radiotracers  in  the  brain  owning  the  capacity  of  crossing
BBB.  A  solution  to  the  BBB  problem  could  be  the  use  of  the  xanthine  phosphoribosyl
transferase  reporter  enzyme  PET  system,  which  employs  xanthine  reporter  probes  that
can  cross  the  BBB  [48].  With  regard  to  in  vivo  NSCs  imaging,  bioluminescence  is  the
most  studied  of  the  optical  imaging  techniques  and  has  been  employed  in  numerous
small animal studies. Improvement of the existing imaging modalities, assessment of the
effect of imaging modalities on cellular biology, and development of new techniques for
in vivo NSC imaging, would open up the window of the use of NSCs for various neuro‐
pathologies.
4.4. Imaging of hematopoietic stem cell transplantation
Hematopoiesis  is  described  to  be  the  production  of  all  types  of  fully  differentiated
daughter  blood cells  from ancestral  great-grandmother hematopoietic  stem cells  (HSCs).
HSCs studies and clinical  applications have historically been ahead of  other tissue stem
cells  and have generated most  stem cell  biology models.  However,  hematopoiesis  is  ar‐
guably among the most difficult of the mammalian stem-cell  systems to image real-time
in vivo  [5].  In homeostatic conditions, the different short-lived cell types of blood are re‐
generated from a small population of HSCs [49],  while a significant proportion of HSCs
with long-term reconstitution potential is predominantly quiescent or divides infrequent‐
ly.  The  HSC  niche  is  most  likely  a  complex,  multi-component  microenvironment  of
which the osteoblast is just one of the major constituents identified so far. Thus, non-in‐
vasive long-term imaging is more challenging in the bone marrow. Hematopoiesis is bet‐
ter  understood than other  stem-cell  systems and has  important  clinical  significance,  but
despite  intensive research in  the past  decade,  many basic  questions  are  still  unresolved
[50].  MRI  [51],  bioluminescence  imaging [52],  and multiphoton fluorescence  microscopy
[53] had been applied in continuous observation of cellular behavior of HSCs. Mentiona‐
ble,  continuous  observation  of  hematopoietic  progenitor  cells  in  the  bone  marrow  was
achieved at single-cell resolution by using multiphoton fluorescence microscopy after the
transplantation,  filling  the  gap  of  low  single  cell  sensitivity  and  resolution  of  the  first
two  modalities.  The  transplantation  option  of  multiphoton  fluorescence  microscopy  is
clinically relevant because HSC transplantation is used to treat patients with hematologi‐
cal malignancies such as leukemia and multiple myeloma. Multiphoton fluorescence mi‐
croscopy was also  used to  observe the  homing of  normal  and malignant  hematopoietic
progenitor  cells  in  the  bone marrow and to  characterize  the  specialized niches  of  these
cells [54].
4.5. Imaging of endothelial progenitor cell therapy
Endothelial progenitor cells (EPCs) recruitment is often involved in the tissue injury trig‐
gered reparative processes, and contribute to healing ischemic tissues. Transplantation of
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EPCs offers the potential for targeted treatment of ischemic diseases such as myocardial [55],
hind-limb ischemia [56], and renal injury [57]. Considerable efforts have been made to moni‐
tor the fate of endothelial progenitor cells fate in vivo using the in vivo molecular imaging
modalities, such as PET [58], computed tomography(CT) [59], MRI [56], BLI [60]. Micro-CT
has been applied in studies of EPCs in rat, pig and human beings. In the research of homing
and renal repair function of EPCs in renovascular disease [59], renal hemodynamics and
function were assessed in pigs by multidetector computed tomography, showing that EPCs
are renoprotective as they attenuated renal dysfunction and damage in chronic atheroscler‐
otic renal artery stenosis, and consequently decreased the injury signals. Based on the previ‐
ous research, maybe CT is promising in clinical application of endothelial progenitor-driven
regeneration.
5. Ideal imaging modalities for stem cell therapy
Currently, none individual imaging modalities can fill the bill of flawless, without limita‐
tions in the spatial and/or temporal resolution or the time span and/or volume that can be
observed in a single experiment.  The use of  direct  labeling,  with labeling agent such as
SPIO or 18F-FDG is hindered by signal decrease, as a result of radio-decay or cell division
or  cell  dispersion.  Additionally,  the  label  may  become  dissociated  from  the  exogenous
stem cell. Thus, direct labeling may not be a reliable means of monitoring long-term cell
viability. On the contrary, this approach is a valid method to observing the stem cell de‐
livery and homing properties. Meanwhile, Reporter gene imaging offers unique capabili‐
ties  for  noninvasive  and  longitudinal  measurement  to  determine  cell  biology  and  cell
viability.
Fundamentally, the choice of modality depends on the questions being addressed (Table
1). If the objective of the research is to image the delivery and early cell localization and
homing of stem cells in different organs, a direct labeling approach may be the answer,
even though potential toxicity must be taken into account. MRI is among the least inva‐
sive  of  available  imaging technologies,  equipped with  expensive  new experimental  ma‐
chines,  which  provide  almost  the  highest  spatial  and  high  temporal  resolution  for
continuous single-cell delivery imaging. But the molecular sensitivity of MRI is lower than
other  modalities  such  as  radionuclide  imaging.  Radionuclide  imaging  modalities  (PET,
SPECT)  have  been  successfully  and  extensively  used  with  high  intrinsic  sensitivity,  al‐
though they may not provide sufficient spatial resolution. On the other hand, if observa‐
tion of stem cell biology and interaction with microenvironment or long-term monitoring
of cell viability is the goal, reporter gene imaging using optical imaging (bioluminescence,
fluorescence), PET/ SPECT imaging, MR imaging appears to be a better option. For exam‐
ple, if a study is about ESCs derived myocyte, use of a reporter gene that is driven by a
promoter that will  only be activated when the cell  has the features of an adult myocyte
(i.e., expresses the sarcomeric protein Troponin T) can provide the information of stem cell
differentiation into goal histiocyte.
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Table 1. The different imaging strategies of stem cell trafficking and guide to finding the appropriate molecular
imaging modalities




Stem-cell-driven regeneration offers tremendous approach for the treatment of intractable
diseases. Tracking the fate of implanted cells is vital to monitor the delivery and viability of
the grafts over extended periods of time. Molecular imaging represents one such tool that
can provide insight into cell survival and proliferation following transplantation into the tis‐
sue. The greatest potential for optimizing imaging approaches for regeneration research
probably lies in applying new insights from stem-cell biology and the development of mo‐
lecular imaging. As experimental techniques and molecular imaging technologies progress,
the potential benefits of regenerative medicine should be a strong motivation to continuous‐
ly improve imaging technology that will enable stem-cell-driven regeneration in mammals
to be more understood. Efforts now should focus on the development of novel labeling
agent and multimodality approaches to increase perception of regenerative medicine, and
promote the clinical translation of these techniques.
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